@article{ad0aa35304754d8b8e1c145f4bf2ec1e,
title = "Performance of the CogState computerized battery in the Mayo Clinic Study on Aging",
abstract = "Introduction The feasibility and validity of brief computerized cognitive batteries at the population-level are unknown. Methods Nondemented participants (n = 1660, age 50-97 years) in the Mayo Clinic Study on Aging completed the computerized CogState battery and standard neuropsychological battery. The correlation between tests was examined and comparisons between CogState performance on the personal computer (PC) and iPad (n = 331), and in the clinic vs. at home (n = 194), were assessed. Results We obtained valid data on greater than 97% of participants on each test. Correlations between the CogState and neuropsychological tests ranged from -0.462 to 0.531. Although absolute differences between the PC and iPad were small and participants preferred the iPad, performance on the PC was faster. Participants performed faster on Detection, One Card Learning, and One Back at home compared with the clinic. Discussion The computerized CogState battery, especially the iPad, was feasible, acceptable, and valid in the population.",
keywords = "Cognitively normal, Computerized cognitive battery, Epidemiology, Mild cognitive impairment, Neuropsychology, Population-based cohort study",
author = "Mielke, {Michelle M.} and Machulda, {Mary M.} and Hagen, {Clinton E.} and Edwards, {Kelly K.} and Roberts, {Rosebud O.} and Pankratz, {V. Shane} and Knopman, {David S.} and Jack, {Clifford R.} and Petersen, {Ronald C.}",
note = "Funding Information: Conflict of Interest Disclosures: Dr. Mielke served as a consultant to Eli Lilly and AbbVie, and receives research support from the NIH/NIA (U01 AG37526, U01 AG06786, P30MH75673, P50 AG44170), the Alzheimer's Drug Discovery Foundation ,and the Michael J. Fox Foundation . Dr. Machulda, Mr. Hagen, Ms. Edwards, Dr. Roberts, and Dr. Pankratz report no disclosures. Dr. Knopman serves as Deputy Editor for Neurology {\textregistered} ; served on a Data Safety Monitoring Board for Lilly Pharmaceuticals; served as a consultant to TauRx Pharmaceuticals; was an investigator in clinical trials sponsored by Baxter, Elan Pharmaceuticals, and Forest Pharmaceuticals in the past 2 years; and receives research support from the NIH (R01 AG41851, U01 AG06786, P50 AG16574). Dr. Jack provides consulting services for Janssen Research & Development, LLC. He receives research funding from the National Institutes of Health (R01 AG011378, R01 AG041851, R01 AG037551, U01 HL096917, U01 AG032438, U01 AG024904), and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation . Dr. Petersen serves on scientific advisory boards for Pfizer, Inc., Janssen Alzheimer Immunotherapy, Roche, Inc., Merck, Inc., and Genentech, Inc.; receives royalties from the publication of Mild Cognitive Impairment (Oxford University Press, 2003); and receives research support from the NIH/NIA . Funding Information: This study was supported by funding from the National Institutes of Health/National Institute on Aging P50 AG016574 , U01 AG006786 , R01 AG041851 , and R01 AG011378 ; the Robert H. and Clarice Smith and Abigail van Buren Alzheimer's Disease Research Program, the Walter S. and Lucienne Driskill Foundation , and was made possible by the Rochester Epidemiology Project (R01 AG034676). The funding organizations did not have a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Publisher Copyright: {\textcopyright} 2015 The Alzheimer's Association.",
year = "2015",
month = nov,
doi = "10.1016/j.jalz.2015.01.008",
language = "English (US)",
volume = "11",
pages = "1367--1376",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "11",
}